Particle size is a measurement choice
- Particle size distribution
- Particle size distribution shows how particle count, mass, or volume is distributed across defined size intervals. In aerosol studies, this distribution is more informative than a single average because different size fractions can affect inhalation, deposition, filtration, and sensor response.3,4,5
Every particle-size result depends on the measurement principle. Laser diffraction calculates a distribution from light-scattering behavior and an optical model. Health-related air sampling often uses inhalable, thoracic, and respirable size fractions. Regulatory inhalation studies may instead focus on aerodynamic particle size because a particle's motion through air determines how emitted material separates in an impactor.1,3,4
For that reason, two instruments can report different values for the same aerosol without either result being incorrect. Each method addresses a specific question: how a particle scatters light, moves through an air stream, responds in an electrical mobility field, or deposits as collected mass in a staged impactor.3,6
Diameter basis changes the answer
| Basis | What it represents | Useful when |
|---|---|---|
| Aerodynamic diameter | Motion of a particle in air compared with a unit-density sphere | Inhalation products, cascade impactors, and health-related sampling fractions |
| Optical-equivalent diameter | Light-scattering response translated through an optical model | Sprays, powders, aerosols, suspensions, and rapid formulation screens |
| Mobility diameter | Particle motion in an electric field after charge conditioning | Fine and ultrafine aerosol measurements where number concentration changes quickly |
| Geometric or image-based diameter | A visible dimension from microscopy or image analysis | Morphology checks, agglomerate review, and particle-shape context |
Laser diffraction can measure many two-phase systems, including powders, sprays, aerosols, suspensions, emulsions, and gas bubbles in liquids. ISO 13320 also defines an important method boundary: for non-spherical particles, the reported distribution is model-based and may differ from distributions measured by sedimentation, sieving, or other physical principles.3
Why aerosol programs care about distribution
For orally inhaled and nasal products, aerodynamic particle-size distribution may form part of the quality and performance evidence. FDA inhalation guidance addresses product quality considerations for MDIs and DPIs. FDA nasal aerosol guidance discusses cascade impactor measurement of particle or droplet size distribution and, for certain suspension products, measurement of drug particle-size distribution by microscopy.1,2,8
- Inhalation and nasal drug-product work may need staged mass, MMAD, GSD, fine-particle dose, or microscopy context depending on product type and study purpose.1,2,8
- Air-quality and exposure work often separates particles by health-related size fractions, including inhalable, thoracic, respirable, PM10, and PM2.5 frames.4,5,7
- Filtration and air-cleaning studies use size-resolved particles because removal, deposition, and sensor response can shift across particle-size intervals.4,7
- Consumer spray and device-development programs use particle-size data to compare formulation, actuator, orientation, plume behavior, and exposure-relevant fractions.3,6
Method selection follows the decision
Early development often calls for fast, comparative measurements. Optical particle sizing, laser diffraction, and real-time aerosol instruments can show whether a formulation, actuator, device setting, or chamber condition changed the distribution enough to warrant more controlled testing.3,6
Screening and troubleshooting
Screening studies work well for comparative questions: Does one nozzle produce a smaller droplet spectrum? Does a device setting change the fine fraction? Does the chamber background interfere with the measurement? Even at the screening stage, flow, timing, background conditions, and instrument checks must be documented so the result can be repeated.3,6
Review-ready studies
Review-ready studies require a clearly defined method. Inhalation products may call for compendial or regulator-aligned impactor testing, while workplace or indoor-air programs may require sampling conventions matched to the exposure question. In either case, method records are part of the evidence, not administrative extras.1,4,6,8
What to define before requesting testing
- Define the product or aerosol source, including device geometry, formulation state, actuation profile, chamber condition, and expected size range.1,3
- State the sizing basis needed for the decision, such as aerodynamic mass, optical volume distribution, mobility number distribution, or microscopy-based morphology.2,3,4
- Identify the report outputs that matter, such as full distributions, percent below a cutoff, MMAD, GSD, Dv10, Dv50, Dv90, or concentration-time data.1,3
- Decide whether the study must support development screening, product comparison, exposure review, quality documentation, or a regulatory submission.1,6
How ARE Labs Connects Particle Size to Study Design
ARE Labs scopes particle-size studies by starting with the decision the data need to support, then selecting the method. A development screen may use laser diffraction or real-time aerosol sizing. A product-quality package may require cascade impactor collection with assay-ready recovery. An exposure or indoor-air study may call for chamber controls, background subtraction, defined size fractions, and complete sampling records.1,3,4,6
The goal is a report that clearly states what was measured, why the sizing basis was selected, which controls were used, and what the results can and cannot support. This distinction helps teams compare devices, troubleshoot aerosols, plan follow-up testing, and avoid overstating a particle-size result.3,6